Sangamo has received research funding from the following sources:
California Institute for Regenerative Medicine
In October 2009, the California Institute for Regenerative Medicine (“CIRM”), a State of California entity, granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of ZFP nuclease (ZFN) gene-editing technology in stem cells. The four year grant supports an innovative research project conducted by a multidisciplinary team of investigators, including investigators from the University of Southern California, City of Hope National Medical Center and Sangamo BioSciences.
The Michael J. Fox Foundation
In January 2007, we announced a partnership with the Michael J. Fox Foundation for Parkinson’s Research (“MJFF”) to provide financial support of Sangamo’s ZFP TFs to activate the expression of glial cell line-derived neurotrophic factor (GDNF) that has shown promise in preclinical testing to slow or stop the progression of Parkinson’s disease. Under the agreement with MJFF and subject to its terms and conditions, MJFF paid the Company $950,000, the total funds due under the agreement, over a period of two years. In June 2010, we received a commitment for renewed funding from MJFF to support further studies of ZFP TF activators of GDNF.
The Juvenile Diabetes Research Foundation International
In October 2006, we announced a partnership with the Juvenile Diabetes Research Foundation International (JDRF) to provide $3.0 million of financial support to one of our Phase 2 human clinical studies (SB-509-601) of SB-509, a ZFP Therapeutic that is in development for the treatment of diabetic neuropathy. In January 2010, JDRF and Sangamo amended the agreement and JDRF will provide additional funding of up to $3.0 million to partially fund expenses related to Sangamo’s Phase 2b trial in diabetic neuropathy (SB-509-901). In October 2011, we announced that we have discontinued further development of SB-509.